Recently, Jiudian Hongyang’s active pharmaceutical ingredient (API) Diacerein (Y20230001269) achieved a status change to "A" on the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), indicating it has successfully passed evaluation and been approved for market launch.

Diacerein, also known as diacetyl dihydroanthracene carboxylic acid, is a novel interleukin-1 (IL-1) inhibitor belonging to the anthraquinone class of compounds. It induces cartilage formation and possesses analgesic, anti-inflammatory, and antipyretic effects. It can also significantly improve joint function in patients with osteoarthritis, delay disease progression, alleviate pain, and enhance patients' quality of life. Compared to traditional non-steroidal anti-inflammatory drugs (NSAIDs), Diacerein not only effectively relieves symptoms and reduces adverse reactions such as peptic ulcers and kidney damage but also has the potential to modify the disease course and improve long-term prognosis. As a result, Diacerein is highly recognized by authoritative clinical institutions and has been included in the Osteoarthritis Diagnosis and Treatment Guidelines issued by the Chinese Orthopaedic Association, the Chinese Rheumatology Association, and the European Alliance of Associations for Rheumatology (EULAR).

The occurrence of osteoarthritis is closely related to age, often affecting middle-aged and elderly people, with main symptoms including joint pain, stiffness, and limited mobility. As the aging population continues to grow, the number of patients is increasing year by year. This large patient population forms a solid foundation for market demand. Diacerein exerts its anti-inflammatory and joint-protective effects by inhibiting the production and release of IL-1β and oxygen free radicals, suppressing the activity of metalloproteinases, and stabilizing lysosomal membranes. It is classified as a slow-acting drug for the treatment of osteoarthritis. Currently, Diacerein capsules are commonly used in clinical practice for osteoarthritis treatment. The approval of its API for market launch will benefit a wide range of patients.

Jiudian Hongyang is committed to building a leading platform for specialty APIs and high-end pharmaceutical excipients, providing more high-quality raw and auxiliary materials to the global market. The approval of Diacerein API marks a new breakthrough for Jiudian Hongyang in the research, development, and production of high-end specialty APIs.